Targeting Pim kinases for cancer treatment: opportunities and challenges.

Pim oncogenes are highly expressed in many types of hematological and solid cancers. Pim kinases regulate the network of signaling pathways that are critical for tumorigenesis and development, making Pim kinases the attractive drug targets. Currently, two approaches have been employed in designing Pim kinase inhibitors: ATP-mimetics and non-ATP mimetics; but all target the ATP-binding pocket and are ATP-competitive. In this review, we summarize the current progress in understanding the Pim-related structure and biology, and provide insights into the binding modes of some prototypical Pim-1 inhibitors. The challenges as well as opportunities are highlighted for development of Pim kinase inhibitors as potential anticancer agents.

[1]  I. Endo,et al.  Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma , 2014, Leukemia.

[2]  S. Kanner,et al.  A Small-Molecule Inhibitor of PIM Kinases as a Potential Treatment for Urothelial Carcinomas , 2014, Neoplasia.

[3]  N. Gray,et al.  Cancer Biology and Signal Transduction Pim Kinases Are Essential for Chronic Lymphocytic Leukemia Cell Survival (pim2/3) and Cxcr4-mediated Microenvironmental Interactions (pim1) , 2022 .

[4]  Allan Wu,et al.  AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. , 2014, Blood.

[5]  Audrey Kauffmann,et al.  Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers , 2014, Clinical Cancer Research.

[6]  Carmen Blanco-Aparicio,et al.  The PIM Family of Serine/Threonine Kinases in Cancer , 2014, Medicinal research reviews.

[7]  V. Viswanadhan,et al.  Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update , 2014, Expert opinion on therapeutic patents.

[8]  E. Casale,et al.  Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases. , 2013, Bioorganic & medicinal chemistry.

[9]  María Martín,et al.  Activities at the Universal Protein Resource (UniProt) , 2013, Nucleic Acids Res..

[10]  T. Paíno,et al.  Dual Antitumoral and Bone Antiresorptive Effect Of The Pan-Pim Kinase Inhibitor, LGH447, In Multiple Myeloma , 2013 .

[11]  A. Jakubowiak,et al.  Phase 1 Study Of The Novel Pan-Pim Kinase Inhibitor LGH447 In Patients With Relapsed/ Refractory Multiple Myeloma , 2013 .

[12]  Yu Ding,et al.  Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors. , 2013, ACS medicinal chemistry letters.

[13]  Y. Qiu,et al.  Pim-1 Kinase Phosphorylates and Stabilizes 130 kDa FLT3 and Promotes Aberrant STAT5 Signaling in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication , 2013, PloS one.

[14]  X. Gou,et al.  The over‐expression of Pim‐2 promote the tumorigenesis of prostatic carcinoma through phosphorylating eIF4B , 2013, The Prostate.

[15]  Ho-Juhn Song,et al.  Crystal Structure of Pim1 Kinase in Complex with a Pyrido[4,3-D]Pyrimidine Derivative Suggests a Unique Binding Mode , 2013, PloS one.

[16]  K. Kuliczkowski,et al.  Expression of PIM-2 and NF-κB genes is increased in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and is associated with complete remission rate and overall survival. , 2013, Postepy higieny i medycyny doswiadczalnej.

[17]  A. Ebens,et al.  Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design. , 2013, Bioorganic & medicinal chemistry letters.

[18]  C. Bieberich,et al.  Stabilization of the prostate‐specific tumor suppressor NKX3.1 by the oncogenic protein kinase Pim‐1 in prostate cancer cells , 2013, Journal of cellular biochemistry.

[19]  Carmen Blanco-Aparicio,et al.  Pim kinases in cancer: diagnostic, prognostic and treatment opportunities. , 2013, Biochemical pharmacology.

[20]  S. Ambudkar,et al.  The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms. , 2013, Biochemical pharmacology.

[21]  Arto Mannermaa,et al.  Proto-oncogene PIM-1 is a novel estrogen receptor target associating with high grade breast tumors , 2013, Molecular and Cellular Endocrinology.

[22]  A. Kraft,et al.  Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice , 2013, Journal of Hematology & Oncology.

[23]  D. Ryckman,et al.  Potential use of selective and nonselective Pim kinase inhibitors for cancer therapy. , 2012, Journal of medicinal chemistry.

[24]  E. Meggers,et al.  Bioactive cyclometalated phthalimides: design, synthesis and kinase inhibition. , 2012, Dalton transactions.

[25]  A. Ferguson,et al.  Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. , 2012, Bioorganic & medicinal chemistry letters.

[26]  Erin A. Maine,et al.  IL-6 Stimulates STAT3 and Pim-1 Kinase in Pancreatic Cancer Cell Lines , 2012, Pancreas.

[27]  D. Ouwens,et al.  Role of PRAS40 in Akt and mTOR signaling in health and disease. , 2012, American journal of physiology. Endocrinology and metabolism.

[28]  S. Kanner,et al.  Abstract 3762: Second generation PIM inhibitors exhibit improved activity in solid tumor models , 2012 .

[29]  Eric Meggers,et al.  PIM1 kinase as a target for cancer therapy , 2012, Expert opinion on investigational drugs.

[30]  J. Oyarzábal,et al.  Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors. , 2012, Bioorganic & medicinal chemistry letters.

[31]  A. Kraft,et al.  Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737. , 2012, Cancer research.

[32]  F. Giles,et al.  The PIM kinases in hematological cancers , 2012, Expert review of hematology.

[33]  F. Giles,et al.  Targeting PIM kinase activity significantly augments the efficacy of cytarabine , 2012, British journal of haematology.

[34]  Kevin Kelly,et al.  The Pim kinases: new targets for drug development. , 2011, Current drug targets.

[35]  Adam Siddiqui-Jain,et al.  7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity. , 2011, Bioorganic & medicinal chemistry letters.

[36]  S. Kanner,et al.  Abstract C200: Second-generation PIM inhibitors exhibit improved activity in solid tumor models in vitro. , 2011 .

[37]  N. V. Zakharevich,et al.  Pim family of protein kinases: Structure, functions, and roles in hematopoietic malignancies , 2011, Molecular Biology.

[38]  J. Jongstra,et al.  The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms. , 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[39]  N. Mukaida,et al.  Roles of Pim‐3, a novel survival kinase, in tumorigenesis , 2011, Cancer science.

[40]  S. Abdulkadir,et al.  Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cells , 2011, Oncogene.

[41]  Varsha Gandhi,et al.  Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. , 2011, Blood.

[42]  Xin Chen,et al.  Discovery of Novel Pim-1 Kinase Inhibitors by a Hierarchical Multistage Virtual Screening Approach Based on SVM Model, Pharmacophore, and Molecular Docking , 2011, J. Chem. Inf. Model..

[43]  Hans Briem,et al.  A crystallographic fragment screen identifies cinnamic acid derivatives as starting points for potent Pim-1 inhibitors. , 2011, Acta crystallographica. Section D, Biological crystallography.

[44]  A. Kraft,et al.  The Pim protein kinases regulate energy metabolism and cell growth , 2010, Proceedings of the National Academy of Sciences.

[45]  Adam Siddiqui-Jain,et al.  CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. , 2010, Cancer research.

[46]  Zhen Xu,et al.  Overexpression of Pim-1 in bladder cancer , 2010, Journal of experimental & clinical cancer research : CR.

[47]  V. Danilenko,et al.  Fighting tumor cell survival: advances in the design and evaluation of Pim inhibitors. , 2010, Current medicinal chemistry.

[48]  Xin Wang,et al.  Overexpression of Pim‐1 is associated with poor prognosis in patients with esophageal squamous cell carcinoma , 2010, Journal of surgical oncology.

[49]  M. Chamberlain,et al.  123 Anti-tumor activity of CXR1002, a novel anti-cancer clinical phase compound that induces ER stress and inhibits PIM kinases: Human tumor xenograft efficacy and in vitro mode of action , 2010 .

[50]  R. Reeves,et al.  Why target PIM1 for cancer diagnosis and treatment? , 2010, Future oncology.

[51]  S. Knapp,et al.  New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[52]  A. Kraft,et al.  p53-Dependent Induction of Prostate Cancer Cell Senescence by the PIM1 Protein Kinase , 2010, Molecular Cancer Research.

[53]  Stefan Knapp,et al.  PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers , 2010, Haematologica.

[54]  M. Salto‐Tellez,et al.  PIM‐1 kinase expression in adipocytic neoplasms: diagnostic and biological implications , 2010, International journal of experimental pathology.

[55]  T. Morwick.  Pim kinase inhibitors: a survey of the patent literature , 2010, Expert opinion on therapeutic patents.

[56]  A. Hölscher,et al.  Prognostic impact of protein overexpression of the proto-oncogene PIM-1 in gastric cancer. , 2009, Anticancer research.

[57]  J. Li,et al.  Pim-1 expression and monoclonal antibody targeting in human leukemia cell lines. , 2009, Experimental hematology.

[58]  Stefan Knapp,et al.  Dissection of PIM serine/threonine kinases in FLT3-ITD–induced leukemogenesis reveals PIM1 as regulator of CXCL12–CXCR4-mediated homing and migration , 2009, The Journal of experimental medicine.

[59]  R. Reeves,et al.  PIM1 Phosphorylates and Negatively Regulates ASK1-mediated Apoptosis , 2009, Oncogene.

[60]  G. Bemis,et al.  Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase. , 2009, Bioorganic & medicinal chemistry letters.

[61]  J. Gong,et al.  Serine/threonine kinase Pim-2 promotes liver tumorigenesis induction through mediating survival and preventing apoptosis of liver cell. , 2009, The Journal of surgical research.

[62]  A. Kraft,et al.  PIM1 Protein Kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells , 2009, Cancer biology & therapy.

[63]  C. Homon,et al.  Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode. , 2009, Journal of medicinal chemistry.

[64]  D. Meek,et al.  14‐3‐3 Binding to Pim‐phosphorylated Ser166 and Ser186 of human Mdm2 – Potential interplay with the PKB/Akt pathway and p14ARF , 2009, FEBS letters.

[65]  Lisa S. Chen,et al.  Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. , 2008, Blood.

[66]  M. Salto‐Tellez,et al.  Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal. , 2008, European journal of cancer.

[67]  D. Bearss,et al.  332 POSTER In vivo activity of SGI-1776, an orally active Pim kinase inhibitor , 2008 .

[68]  Z. Wang,et al.  Pim kinase-dependent inhibition of c-Myc degradation , 2008, Oncogene.

[69]  T. Tsuruo,et al.  Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. , 2008, Cancer research.

[70]  M. Saville,et al.  Elevated Levels of Oncogenic Protein Kinase Pim-1 Induce the p53 Pathway in Cultured Cells and Correlate with Increased Mdm2 in Mantle Cell Lymphoma* , 2008, Journal of Biological Chemistry.

[71]  M. Tomasson,et al.  The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. , 2008, Blood.

[72]  K. Tsuneyama,et al.  Aberrant Pim-3 expression is involved in gastric adenoma–adenocarcinoma sequence and cancer progression , 2008, Journal of Cancer Research and Clinical Oncology.

[73]  Zhiyong Guo,et al.  The 44-kDa Pim-1 Kinase Phosphorylates BCRP/ABCG2 and Thereby Promotes Its Multimerization and Drug-resistant Activity in Human Prostate Cancer Cells* , 2008, Journal of Biological Chemistry.

[74]  S. Knapp,et al.  A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases , 2007, Proceedings of the National Academy of Sciences.

[75]  N. Magnuson,et al.  Pim-1 Kinase-Dependent Phosphorylation of p21Cip1/WAF1 Regulates Its Stability and Cellular Localization in H1299 Cells , 2007, Molecular Cancer Research.

[76]  S. Knapp,et al.  Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. , 2007, Cancer research.

[77]  K. Tsuneyama,et al.  Proto‐oncogene, Pim‐3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad‐mediated apoptosis , 2007, Cancer science.

[78]  M. Lilly,et al.  Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase , 2007, Molecular Cancer Therapeutics.

[79]  H. Bregman,et al.  Ruthenium half-sandwich complexes as protein kinase inhibitors: an N-succinimidyl ester for rapid derivatizations of the cyclopentadienyl moiety. , 2006, Organic letters.

[80]  Kyu-Tae Kim,et al.  Constitutively activated FLT3 phosphorylates BAD partially through Pim‐1 , 2006, British journal of haematology.

[81]  Hiroshi Ishikura,et al.  Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines. , 2006, Cancer research.

[82]  M. Nawijn,et al.  Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL. , 2006, Cancer research.

[83]  J. Eble,et al.  Overexpression of Pim-1 during progression of prostatic adenocarcinoma , 2006, Journal of Clinical Pathology.

[84]  S. Knapp,et al.  Structure and Substrate Specificity of the Pim-1 Kinase* , 2005, Journal of Biological Chemistry.

[85]  S. Knapp,et al.  Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase. , 2005, Journal of medicinal chemistry.

[86]  L. Pinna,et al.  Autophosphorylation at the regulatory β subunit reflects the supramolecular organization of protein kinase CK2 , 2005, Molecular and Cellular Biochemistry.

[87]  M. Fleming,et al.  Pim-1 Ligand-bound Structures Reveal the Mechanism of Serine/Threonine Kinase Inhibition by LY294002* , 2005, Journal of Biological Chemistry.

[88]  Yoshihisa Suzuki,et al.  Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma. , 2005, Journal of molecular biology.

[89]  T. Möröy,et al.  The serine/threonine kinase Pim-1. , 2005, The international journal of biochemistry & cell biology.

[90]  Shuichi Kaneko,et al.  Aberrant expression of serine/threonine kinase Pim‐3 in hepatocellular carcinoma development and its role in the proliferation of human hepatoma cell lines , 2005, International journal of cancer.

[91]  N. Magnuson,et al.  Pim-1 Kinase Stability Is Regulated by Heat Shock Proteins and the Ubiquitin-Proteasome Pathway , 2005, Molecular Cancer Research.

[92]  Jun Li,et al.  Structural Basis of Constitutive Activity and a Unique Nucleotide Binding Mode of Human Pim-1 Kinase* , 2005, Journal of Biological Chemistry.

[93]  P. Meltzer,et al.  Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. , 2005, Blood.

[94]  Lin Ying Liu,et al.  IL-5 and Granulocyte-Macrophage Colony-Stimulating Factor Activate STAT3 and STAT5 and Promote Pim-1 and Cyclin D3 Protein Expression in Human Eosinophils1 , 2004, The Journal of Immunology.

[95]  P. Ekman,et al.  Pim‐1 expression in prostatic intraepithelial neoplasia and human prostate cancer , 2004, The Prostate.

[96]  P. Koskinen,et al.  Pim‐1 kinase promotes inactivation of the pro‐apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site , 2004, FEBS letters.

[97]  Jos Jonkers,et al.  Mice Deficient for All PIM Kinases Display Reduced Body Size and Impaired Responses to Hematopoietic Growth Factors , 2004, Molecular and Cellular Biology.

[98]  O. Silvennoinen,et al.  Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3. , 2004, Blood.

[99]  B. Gary,et al.  Overexpression of the oncogenic kinase Pim-1 leads to genomic instability. , 2003, Cancer research.

[100]  E. White.  The pims and outs of survival signaling: role for the Pim-2 protein kinase in the suppression of apoptosis by cytokines. , 2003, Genes & development.

[101]  Bao Q. Vuong,et al.  Protein Phosphatase 2A Regulates the Stability of Pim Protein Kinases* , 2003, The Journal of Biological Chemistry.

[102]  Wenyi Wei,et al.  Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. , 2002, Biochimica et biophysica acta.

[103]  M. Wasik,et al.  Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis. , 2002, Blood.

[104]  Z. Wang,et al.  Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. , 2001, Journal of veterinary science.

[105]  Gouri Nanjangud,et al.  Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas , 2001, Nature.

[106]  S R Datta,et al.  14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. , 2000, Molecular cell.

[107]  K. Alitalo,et al.  Developmental expression of Pim kinases suggests functions also outside of the hematopoietic system , 2000, Oncogene.

[108]  G. Mills,et al.  Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway , 1999, Oncogene.

[109]  A. Kraft,et al.  The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway , 1999, Oncogene.

[110]  K. Noguchi,et al.  Physical and Functional Interactions between Pim-1 Kinase and Cdc25A Phosphatase , 1999, The Journal of Biological Chemistry.

[111]  P. Koskinen,et al.  Interferon- Activates Multiple STAT Proteins and Upregulates Proliferation-Associated IL-2R, c-myc, and pim-1 Genes in Human T Cells , 1999 .

[112]  M. Baudry,et al.  Seizure activity induces PIM‐1 expression in brain , 1998, Journal of neuroscience research.

[113]  C. Peng,et al.  C-TAK1 protein kinase phosphorylates human Cdc25C on serine 216 and promotes 14-3-3 protein binding. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[114]  R. Reeves,et al.  Pim-1 protein expression is regulated by its 5'-untranslated region and translation initiation factor elF-4E. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[115]  Elizabeth Yang,et al.  Serine Phosphorylation of Death Agonist BAD in Response to Survival Factor Results in Binding to 14-3-3 Not BCL-XL , 1996, Cell.

[116]  H. Broxmeyer,et al.  Transcriptional induction of pim-1 protein kinase gene expression by interferon gamma and posttranscriptional effects on costimulation with steel factor. , 1995, Blood.

[117]  P. Laird,et al.  Pim-1 levels determine the size of early B lymphoid compartments in bone marrow , 1993, The Journal of experimental medicine.

[118]  A. Berns,et al.  The pim‐1 oncogene encodes two related protein‐serine/threonine kinases by alternative initiation at AUG and CUG. , 1991, The EMBO journal.

[119]  C. Croce,et al.  Characterization of the human PIM-1 gene: a putative proto-oncogene coding for a tissue specific member of the protein kinase family. , 1987, Oncogene research.

[120]  Wim Quint,et al.  Murine leukemia virus-induced T-cell lymphomagenesis: Integration of proviruses in a distinct chromosomal region , 1984, Cell.

[121]  M. Nawijn,et al.  For better or for worse: the role of Pim oncogenes in tumorigenesis , 2011, Nature Reviews Cancer.

[122]  L. Pinna,et al.  Autophosphorylation at the regulatory beta subunit reflects the supramolecular organization of protein kinase CK2. , 2005, Molecular and cellular biochemistry.

[123]  水野 克典.  Regulation of Pim-1 by Hsp90 , 2001 .

[124]  P. Koskinen,et al.  Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. , 1999, Blood.

[125]  M. Kashiwada,et al.  IL-4 signaling is regulated through the recruitment of phosphatases, kinases, and SOCS proteins to the receptor complex. , 1999, Cold Spring Harbor symposia on quantitative biology.